We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Encompass Health Expands Rehab Footprint With New Maine Hospital
Read MoreHide Full Article
Key Takeaways
EHC opened its first wholly owned Maine hospital, adding 50 beds for inpatient rehabilitation.
EHC's Q2 2026 discharges rose 5.6%, driven by new capacity and 2.8% same-store growth.
EHC opened three hospitals in the first half and plans eight new hospitals in 2026.
Encompass Health Corporation (EHC - Free Report) has expanded its inpatient rehabilitation footprint with the opening of Encompass Health Rehabilitation Hospital of Bangor in Maine. The 50-bed facility is now accepting patients and marks the company’s first wholly owned hospital in the state. The hospital provides specialized rehabilitation for patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions.
The hospital offers physical, occupational and speech therapy, along with 24-hour nursing care and frequent physician visits. Its facilities include private rooms, an advanced therapy gym, an activities of daily living suite, an in-house dialysis unit, a pharmacy and outdoor therapy areas. The location is also expected to expand access to post-acute rehabilitation while potentially easing capacity constraints at acute-care hospitals in the Bangor area.
The Bangor opening fits EHC’s broader strategy of adding capacity in markets where demand for inpatient rehabilitation remains favorable. In the second quarter of 2026, total discharges increased 5.6% year over year, while same-store discharges grew 2.8%, indicating that volume growth was driven by both new capacity and organic growth at existing hospitals. Net patient revenue per discharge also increased 3.9%, providing an additional boost to revenue growth.
EHC opened three hospitals totaling 139 beds in the first half of 2026 and added 54 beds through expansions at existing hospitals. The company plans to open eight new hospitals in 2026. The pace reflects EHC’s continued focus on growing its hospital network and increasing its bed capacity.
The Bangor facility could strengthen EHC’s long-term growth runway by adding capacity in a new wholly owned market while complementing its existing joint-venture presence in Portland. However, the returns from new hospitals will depend on how quickly beds ramp up and staffing costs are absorbed. With more openings planned this year, execution will remain key to sustaining EHC’s growth momentum.
EHC’s Price Performance
Year to date, EHC’s shares have gained 17.5% compared with the industry’s growth of 21%.
The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.
View the Zacks #1 Rank List
Image: Shutterstock
Encompass Health Expands Rehab Footprint With New Maine Hospital
Key Takeaways
Encompass Health Corporation (EHC - Free Report) has expanded its inpatient rehabilitation footprint with the opening of Encompass Health Rehabilitation Hospital of Bangor in Maine. The 50-bed facility is now accepting patients and marks the company’s first wholly owned hospital in the state. The hospital provides specialized rehabilitation for patients recovering from strokes, brain injuries, spinal cord injuries, amputations and complex orthopedic conditions.
The hospital offers physical, occupational and speech therapy, along with 24-hour nursing care and frequent physician visits. Its facilities include private rooms, an advanced therapy gym, an activities of daily living suite, an in-house dialysis unit, a pharmacy and outdoor therapy areas. The location is also expected to expand access to post-acute rehabilitation while potentially easing capacity constraints at acute-care hospitals in the Bangor area.
The Bangor opening fits EHC’s broader strategy of adding capacity in markets where demand for inpatient rehabilitation remains favorable. In the second quarter of 2026, total discharges increased 5.6% year over year, while same-store discharges grew 2.8%, indicating that volume growth was driven by both new capacity and organic growth at existing hospitals. Net patient revenue per discharge also increased 3.9%, providing an additional boost to revenue growth.
EHC opened three hospitals totaling 139 beds in the first half of 2026 and added 54 beds through expansions at existing hospitals. The company plans to open eight new hospitals in 2026. The pace reflects EHC’s continued focus on growing its hospital network and increasing its bed capacity.
The Bangor facility could strengthen EHC’s long-term growth runway by adding capacity in a new wholly owned market while complementing its existing joint-venture presence in Portland. However, the returns from new hospitals will depend on how quickly beds ramp up and staffing costs are absorbed. With more openings planned this year, execution will remain key to sustaining EHC’s growth momentum.
EHC’s Price Performance
Year to date, EHC’s shares have gained 17.5% compared with the industry’s growth of 21%.
Image Source: Zacks Investment Research
EHC’s Zacks Rank & Other Key Picks
EHC currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the Medical space are Concentra Group Holdings Parent, Inc. (CON - Free Report) , Phibro Animal Health Corporation (PAHC - Free Report) and GeneDx Holdings Corp. (WGS - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
The Zacks Consensus Estimate for Concentra Group’s current-year earnings of $1.65 per share has witnessed two upward revisions in the past 30 days against no movement in the opposite direction. CON beat earnings estimates in each of the trailing four quarters, with the average surprise being 16.3%. The consensus estimate for current-year revenues is pegged at $2.4 billion, suggesting 8.7% year-over-year growth.
The Zacks Consensus Estimate for Phibro Animal Health’s current-year earnings of $3.50 per share has witnessed one upward revision in the past 30 days against no movement in the opposite direction. PAHC beat earnings estimates in each of the trailing four quarters, with the average surprise being 18.4%. The consensus estimate for current-year revenues is pegged at $1.6 billion, suggesting 3.8% year-over-year growth.
The Zacks Consensus Estimate for GeneDx Holdings’ current-year earnings of 11 cents per share has witnessed one upward revision in the past 60 days against no movement in the opposite direction. WGS beat earnings estimates in three of the trailing four quarters and missed once. The consensus estimate for current-year revenues is pegged at $478 million, suggesting 11.8% year-over-year growth.